Relapsed/Refractory
Criteria to qualify for study: | Drug used in study: |
---|---|
|
Hemref 43 Trillium A Phase 1a/1b Dose Escalation and Expansion Trial of Single agen TTI-621, a Novel Biologic Targeting CD47, in Subjects with Relapsed of Refractory Hematologic Malignancies |
Criteria to qualify for study: | Drug used in study: |
---|---|
|
BMT 24: A Phase 2 Single Arm Study of Nivolumab as consolidation therapy after Autologous stem cell transplantation in patients with Hodgkin Lymphomas at risk of relapse of progression. |